Propanc Biopharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on October 16, 2023, covering events occurring on October 12, 2023. Propanc Biopharma, Inc., a Delaware corporation with its principal executive office in Camberwell, Australia, entered into a material definitive agreement to secure financing for general working capital purposes.
Key Financial Metrics and Transaction Details
- Instrument: Convertible Redeemable Promissory Note.
- Principal Amount: $61,000.
- Purchase Price: $57,500 (issued at a discount).
- Interest Rate: 8% per annum (increases to 24% upon default).
- Maturity Date: April 12, 2024.
- Interest Payment: Payable only in Common Stock.
- Conversion Price: Initial fixed price of $0.015 per share, subject to reduction to $0.0075 if the market price trades below $0.01 for more than five consecutive trading days.
- Prepayment Terms: Company may prepay within 180 days at a premium ranging from 110% to 125% of the face amount plus accrued interest; no prepayment right exists after 180 days.
Material Changes and Terms
The filing discloses the creation of a direct financial obligation. The Note includes a "lookback" provision where, in the event of default, the conversion price adjusts to the lowest trading price of the Common Stock over the ten trading days preceding the default. Additionally, if the Company loses its "bid" price on an OTC market, the outstanding principal amount increases by 20%. The Company is required to maintain a reserve of at least 400% of the number of Conversion Shares.
Outlook, Risks, and Contingencies
- Redemption Trigger: In the event of a sale of substantially all assets or certain mergers, the Investor may request redemption for 150% of the principal and accrued interest or immediate conversion.
- Events of Default: Include failure to issue shares, loss of OTC listing or bid price, failure to comply with SEC reporting, insolvency, or breach of covenants. Default renders the Note immediately due and payable.
- Ownership Limitation: Conversions are subject to a 4.99% beneficial ownership limitation, extendable to 9.9% with 60 days' notice.
- Financial Statements: The filing does not provide updated revenue, profit, cash flow, or liquidity metrics beyond the specific terms of this transaction.
Investor Verification Checklist
- Verify the current market price of Propanc Biopharma's Common Stock to assess the likelihood of the conversion price reducing to $0.0075.
- Confirm the Company's continued compliance with SEC reporting requirements and OTC listing status to avoid default triggers.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) and the Note (Exhibit 4.1) for specific covenants and representations.
- Assess the dilution impact of the 400% share reserve requirement and potential conversion at the lower fixed price.